Cardiovascular and Hematologic Complications of COVID-19 Vaccines

Area of Science:

• Immunology
• Cardiology
• Hematology

Background:

• COVID-19 presents significant prothrombotic and cardiac risks.
• Four major COVID-19 vaccines (mRNA and adenovirus vector) are approved in North America.
• While effective, these vaccines have been linked to specific adverse events.

Purpose of the Study:

• To review known complications associated with COVID-19 vaccines.
• To differentiate between vaccine-induced thrombotic thrombocytopenia (VITT) and secondary immune thrombocytopenic purpura.
• To discuss cardiac complications like myocarditis and pericarditis post-vaccination.

Main Methods:

• Review of current literature on COVID-19 vaccine adverse events.
• Comparative analysis of VITT and secondary immune thrombocytopenic purpura.
• Summary of reported cardiac side effects following vaccination.

Main Results:

• Vaccine-induced thrombotic thrombocytopenia (VITT), distinct from heparin-induced thrombocytopenia, is associated with adenovirus vector vaccines.
• Secondary immune thrombocytopenic purpura occurs with all vaccine types, lacking platelet activation.
• Myocarditis and pericarditis are reported post-mRNA vaccination, particularly in young males, with generally good recovery.

Conclusions:

• Long-term effects of VITT, secondary ITP, myocarditis, and pericarditis require further investigation.
• Continuous monitoring for vaccine complications is essential for diagnosis and management.
• Physician consultation is recommended for patients experiencing adverse effects before receiving further vaccine doses.